STANOZOLOL (WINSTROL)

Stanozolol 10 is an oral androgen derived from dihydrotestosterone. Stanozolol 10 acts on
androgen receptors to promote anabolism through increased nitrogen retention and protein
synthesis in muscle tissue. Stanozolol 10 is a strong anabolic substance with androgenic
action. Stanozolol does not convert to estrogen and therefore does not produce typical
estrogen mediated side effects such as water retention. Stanozolol has a large oral
bioavailability, due to a C17 a-alkylation which allows the hormone to survive first pass liver
metabolism. Stanozolol reduces SHBG increasing free testosterone levels.

  • 30.00

Description

Stanozolol

Strength: 10 mg
Molecular Formula: C21H32N20
Molecular Weight: 328.49 g/mol
Active Ingredient: Stanozolol
CAS number: 10418-03-8
Dosage Form: Tablet
Route: Oral
Market Status: Prescription
Company: Hilma Biocare

DESCRIPTION

Stanozolol 10 is an oral androgen derived from dihydrotestosterone. Stanozolol 10 acts on
androgen receptors to promote anabolism through increased nitrogen retention and protein
synthesis in muscle tissue. Stanozolol 10 is a strong anabolic substance with androgenic
action. Stanozolol does not convert to estrogen and therefore does not produce typical
estrogen mediated side effects such as water retention. Stanozolol has a large oral
bioavailability, due to a C17 a-alkylation which allows the hormone to survive first pass liver
metabolism. Stanozolol reduces SHBG increasing free testosterone levels.

CLINICAL PHARMACOLOGY

Anabolic steroids are synthetic derivatives of the natural steroid testosterone. Stanozolol has
been demonstrated to increase LDL and decrease HDL with serum lipid values returning to
baseline after cessation of use.Hereditary angioedema (HAE) is an autosomal dominant
disorder caused by a deficient or nonfunctional C1 esterase inhibitor (C1 INH) and is
clinically characterized by episodes of swelling of the face, extremities, genitalia, bowel wall,
and upper respiratory tract. In small clinical studies, stanozolol was effective in controlling
the frequency and severity of attacks of angioedema and in increasing serum levels of C1
INH and C4. Stanozolol is not effective in stopping HAE TAS attacks while they are
underway. The effect of stanozolol on increasing serum levels of C1 INH and C4 may be
related to an increase in protein anabolism.

INDICATIONS

Hereditary Angioedema: for prophylactic use to decrease frequency and severity of attacks
of angioedema. Muscle Anabolism: for adjunctive therapy in patients for weight gain
following severe muscular atrophy associated with extensive surgery, chronic infections,
long term hospitali- zation, or severe trauma. Corticosteroid Atrophy: to reduce muscle
wasting during prolonged corticosteroid use.

CONTRAINDICATIONS

Not for use in female patients due to risk of virilization and fetal harm. Male patients with
known or suspected carcinoma of the breast, prostate, or testis. Patients with
hypercalcaemia as anabolic steroids may stimulate osteolytic bone resorption. Patients with
cardiovascular disorders, renal or hepatic impairment, epilepsy, migraines, or diabetes
mellitus. Nephrosis or the nephrotic phase of nephritis.

PRECAUTIONS

Anabolic steroids may cause suppression of clotting factors II, V. VILand X and an increase
in prothrombin time. Anabolic steroids may increase sensitivity to anticoagulants. Dosage of
anticoagulants may have to be decreased in order to maintain the prothrombin time at the
desired therapeutic level. Oral hypoglycemic dosage may need adjustment in diabetic
patients who receive anabolic steroids. Patients using C17 a-alkylated oral steroids should
be monitored for hepatotoxicity and jaundicing.

ADVERSE REACTIONS

Hepatic: Cholestatic jaundice with rarely, hepatic necrosis and death. Hepatocellular
neoplasms and peliosis hepatis have been reported in associa- tion with long term
androgenic anabolic steroid use. Reversible changes in liver function tests also occur
including increased bromsulphalein (BSP) retention and increases in serum bilirubin,
glutamic oxaloacetic transami- nase (SGOT), and alkaline phosphatase. Genitourinary
System (post pubertal men): Inhibition of testicular functions, testicular atrophy, and
oligospermia, impotence, chronic priapism, epididymitis and bladder irritability. Genitourinary
System (Women): Clitoral enlargement, menstrual irregularities. In both sexes: increased or
decreased libido. CNS: Habituation, excitation, insomnia, and depression. Hematologic:
Bleeding in patients on concomitant anticoagulant therapy. Hair: Hirsutism and male pattern
baldness in those genetically predisposed. Other: Acne, oily skin, electrolytic retention,
reversible changes in serum lipids.

PATIENT MONITORING

Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests –
AST/ALT Prostatic specific antigen – PSA, Testosterone: total, free, and bioavailable.
Dihydrotestosterone & Estradiol. Male patients over 40 should undergo a digital rectal.
examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate
should continue while on androgen therapy, especially in patients with difficulty in urination
or with changes in voiding habits.

DOSAGE AND ADMINISTRATION

Muscle anabolism: 10 30mg taken orally each day in divided doses for a duration of 4 -6
weeks. Hereditary angioedema: 2 – 6 mg taken orally each day in divided doses initially &
reduced by physician thereafter. The use of anabolic steroids is associated with serious
adverse reactions. Such reactions are often dose dependent. Physicians are urged to treat
patients with the lowest possible effective dose.

PRESENTATION

Stanozolol 10 mg uncoated tablets: 100 tablets in 1 bottle.

STORAGE

Store in a cool dry place between 15 -25°C. Protect from light.

Reviews

There are no reviews yet.

Be the first to review “STANOZOLOL (WINSTROL)”

Your email address will not be published. Required fields are marked *

*
*

en English
X
Have no product in the cart!
0